Innocan Pharma Corporation is set to present groundbreaking findings at the upcoming PAINWeek 2025 Conference in Las Vegas, Nevada. The company will showcase a scientific poster detailing key data on LPT-CBD pharmacokinetics and efficacy, along with a recently published narrative review highlighting the potential of long-acting synthetic Cannabidiol (CBD) for chronic pain management. This presentation comes at a critical time as the healthcare industry seeks non-opioid alternatives to address the ongoing opioid crisis.
PAINWeek is a renowned national conference that gathers leading experts in pain medicine to share innovative research and best practices. Innocan’s narrative review, selected through a rigorous peer-review process, sheds light on the benefits of synthetic CBD delivered through extended-release formulations as a well-tolerated, non-opioid analgesic option. The event provides an ideal platform to introduce Innocan’s LPT-CBD, an injectable liposomal drug product designed for sustained CBD release, which has shown promising results in preclinical studies.
The endocannabinoid system’s role in pain modulation is well-established, and Innocan’s synthetic CBD platform offers a novel approach to leveraging this pathway for chronic pain relief. With opioid dependency posing a significant global health challenge, the development of LPT-CBD as a safe and effective non-opioid therapy could revolutionize chronic pain management. By ensuring steady plasma CBD levels for extended periods, LPT-CBD aims to provide prolonged pain relief while maintaining excellent tolerability—a crucial factor in patient care.
In addition to its pharmaceutical innovations, Innocan is actively engaged in the wellness sector, offering a range of high-performance self-care and beauty products to promote a healthier lifestyle. Through its subsidiary, BI Sky Global Ltd., the company focuses on advanced online sales strategies to reach a wider consumer base. This dual focus on pharmaceutical advancements and wellness products underscores Innocan’s commitment to enhancing overall well-being through innovation and research.
The presentation of LPT-CBD at PAINWeek will not only showcase the potential of this novel therapy to healthcare professionals but also open avenues for strategic partnerships within the pharmaceutical industry. As Innocan positions itself at the forefront of non-opioid chronic pain management solutions, the company’s dedication to evidence-based research and contribution to the field of pain care is reaffirmed. The recognition of presenting at PAINWeek reflects Innocan’s ongoing commitment to advancing healthcare through cutting-edge solutions.
Key Takeaways:
1. Innocan’s LPT-CBD offers a promising alternative to opioid medications for chronic pain management.
2. The presentation at PAINWeek 2025 highlights the potential of synthetic CBD in extended-release formulations.
3. By targeting the endocannabinoid system, Innocan’s innovative approach could address the global opioid crisis.
4. The company’s dual focus on pharmaceutical developments and wellness products demonstrates a comprehensive commitment to improving patient outcomes and well-being.
Tags: regulatory, drug delivery
Read more on newswire.ca